HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 111, Issue 51, Pages 18297-18302
Publisher
Proceedings of the National Academy of Sciences
Online
2014-12-09
DOI
10.1073/pnas.1421323111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Reprogramming of Tumor Stroma by HSF1 Is a Potent Enabler of Malignancy
- (2014) Ruth Scherz-Shouval et al. CELL
- The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
- (2014) Suqin He et al. INVESTIGATIONAL NEW DRUGS
- mTOR Inhibition Potentiates HSP90 Inhibitor Activity via Cessation of HSP Synthesis
- (2014) Jaime Acquaviva et al. MOLECULAR CANCER RESEARCH
- Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
- (2014) J. Acquaviva et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Heterogeneity Confounds and Illuminates: A case for Darwinian tumor evolution
- (2014) Kornelia Polyak NATURE MEDICINE
- Combating Evolution to Fight Disease
- (2014) S. M. Rosenberg et al. SCIENCE
- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
- (2014) M. Yu et al. SCIENCE
- The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models
- (2013) N. Miyajima et al. CANCER RESEARCH
- Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
- (2013) Julie C. Friedland et al. INVESTIGATIONAL NEW DRUGS
- The search for ESR1 mutations in breast cancer
- (2013) Steffi Oesterreich et al. NATURE GENETICS
- Potential of the Synthetic Lethality Principle
- (2013) S. M. B. Nijman et al. SCIENCE
- Cryptic Variation in Morphological Evolution: HSP90 as a Capacitor for Loss of Eyes in Cavefish
- (2013) N. Rohner et al. SCIENCE
- Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer
- (2013) Jim Sang et al. Cancer Discovery
- Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
- (2013) Benjamin Matteson Vincent et al. PLOS BIOLOGY
- Catalysis of Protein Folding by Chaperones Accelerates Evolutionary Dynamics in Adapting Cell Populations
- (2013) Murat Çetinbaş et al. PLoS Computational Biology
- Evolutionary dynamics of cancer in response to targeted combination therapy
- (2013) Ivana Bozic et al. eLife
- AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies
- (2012) Cynthie Wong et al. BREAST CANCER RESEARCH AND TREATMENT
- Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition
- (2012) Mikko Taipale et al. CELL
- HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers
- (2012) Marc L. Mendillo et al. CELL
- The expanding proteome of the molecular chaperone HSP90
- (2012) Rahul S. Samant et al. CELL CYCLE
- Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies
- (2012) Ryan P Roop et al. Future Oncology
- Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
- (2011) Thomas De Raedt et al. CANCER CELL
- Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition
- (2011) T. Bachleitner-Hofmann et al. CLINICAL CANCER RESEARCH
- Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor-Positive Metastatic Breast Cancer: A Randomized Phase II Study
- (2011) C. K. Osborne et al. CLINICAL CANCER RESEARCH
- Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
- (2011) W. Ying et al. MOLECULAR CANCER THERAPEUTICS
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- Hsp90 and Environmental Stress Transform the Adaptive Value of Natural Genetic Variation
- (2010) D. F. Jarosz et al. SCIENCE
- Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease
- (2009) Leah E. Cowen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis
- (2008) Marissa V. Powers et al. CANCER CELL
- Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts
- (2008) C. J. Creighton et al. CANCER RESEARCH
- Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
- (2008) S. Massarweh et al. CANCER RESEARCH
- Optimizing Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: Treating the Right Patients for the Right Length of Time
- (2008) Nancy U. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started